12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Company News  |  Deals

Biotech Synergy deal

Biotech Synergy acquired cancer candidate EP-2101 from an undisclosed company. The vaccine containing nine cytotoxic T lymphocyte epitopes from four tumor associated antigens (TAA) has...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >